GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » ROIC %

IN8bio (IN8bio) ROIC % : -287.20% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IN8bio ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. IN8bio's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -287.20%.

As of today (2024-06-05), IN8bio's WACC % is 9.36%. IN8bio's ROIC % is -256.86% (calculated using TTM income statement data). IN8bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.


IN8bio ROIC % Historical Data

The historical data trend for IN8bio's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio ROIC % Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -793.42 -451.08 -360.25 -309.19 -234.04

IN8bio Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -233.90 -249.77 -228.79 -256.65 -287.20

Competitive Comparison of IN8bio's ROIC %

For the Biotechnology subindustry, IN8bio's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's ROIC % distribution charts can be found below:

* The bar in red indicates where IN8bio's ROIC % falls into.



IN8bio ROIC % Calculation

IN8bio's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-30.337 * ( 1 - 0% )/( (13.654 + 12.271)/ 2 )
=-30.337/12.9625
=-234.04 %

where

IN8bio's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-34.58 * ( 1 - 0% )/( (12.271 + 11.81)/ 2 )
=-34.58/12.0405
=-287.20 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IN8bio  (NAS:INAB) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, IN8bio's WACC % is 9.36%. IN8bio's ROIC % is -256.86% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


IN8bio ROIC % Related Terms

Thank you for viewing the detailed overview of IN8bio's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio (IN8bio) Business Description

Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Executives
Jeremy R. Graff director C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall officer: Chief Financial Officer C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho director, officer: President, CEO and CFO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l. director, 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc 10 percent owner 10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb officer: EVP and CSO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami officer: Chief Medical Officer C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin officer: Chief Operating Officer IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118